An Effect Size Primer: A Guide for Clinicians and Researchers

Christopher J. Ferguson
Texas A&M International University

Increasing emphasis has been placed on the use of effect size reporting in the analysis of social science data. Nonetheless, the use of effect size reporting remains inconsistent, and interpretation of effect size estimates continues to be confused. Researchers are presented with numerous effect sizes estimate options, not all of which are appropriate for every research question. Clinicians also may have little guidance in the interpretation of effect sizes relevant for clinical practice. The current article provides a primer of effect size estimates for the social sciences. Common effect sizes estimates, their use, and interpretations are presented as a guide for researchers.

Keywords: effect size (statistical), null hypothesis testing, experimentation, statistical analysis, statistical significance, practical significance

By the 1990s, statisticians had been aware for some time that null-hypothesis significance testing (NHST) was, in many respects, insufficient for interpreting social science data (Berkson, 1938; Cohen, 1994; Loftus, 1996; Lykken, 1968; Meehl, 1978; Snyder & Lawson, 1993). Subsequently the Wilkinson Task Force (Wilkinson & Task Force on Statistical Inference, 1999) recommended the reporting of effect sizes and effect size confidence intervals (CIs). Nonetheless, the use of effect size measures remains inconsistent (Fidler et al., 2005; Osborne, 2008; Sink & Stroh, 2006). Researchers and clinicians may find themselves with little guidance as to how to select from among a multitude of available effect sizes, interpret data from research, or gauge the practical utility of reported effect sizes. The current article seeks to provide a primer for clinicians and researchers in understanding effect size reporting and interpretation.

The Purpose of Effect Size Reporting

NHST, has long been regarded as an imperfect tool for examining data (e.g., Cohen, 1994; Loftus, 1996). Statistical significance of NHST is the product of several factors: the “true” effect size in the population, the size of the sample used, and the alpha (p) level selected. Limitations of NHST include sensitivity to sample size, inability to accept the null hypothesis, and the failure of NHST to determine the practical significance of statistical relationships (Cohen, 1992, 1994; Loftus, 1996; Osborne, 2008).

Kirk (1996) puts the limitations of NHST succinctly in noting that they fall under three main categories:

First, NHST does not adequately answer research questions. Regarding falsify-ability, scientists need to know the probability that a null hypothesis is true, given a data set. Unfortunately, NHST tells us the opposite, namely how likely a data set is to have occurred, given that the null hypothesis is true (Cohen, 1994; Kirk, 1996).

Second, no two sample means are ever identical (Tukey, 1991). The null hypothesis is, on a microscopic level at least, always false (Kirk, 1996). The result is the quixotic quest for power to demonstrate any difference as statistically significant without considering whether small differences are meaningful. This is particularly an issue when sample selection is nonrandom as sampling error is underestimated in NHST when sampling is nonrandom. NHST risks becoming something of a “trivial exercise” as a result (Kirk, 1996, p. 747).

Third, the .05 p level is arbitrary, leading researchers to come to different conclusions from equal treatment effects (Kirk, 1996). A researcher who finds that a treatment effect is nonsignificant using a sample of 100 participants, randomly assigned, may find that simply adding 100 more participants produces statistically significant effects, even though the treatment effects remain identical. This criticism is put most eloquently in Rosnow and Rosenthal’s (1989) famous quote “Surely God loves the .06 nearly as much as the .05” (p. 1277).

At present, no clear replacement for NHST has emerged. However, the Wilkinson Task Force (1999) recommends the use of effect size in addition to NHST.

Effect sizes estimate the magnitude of effect or association between two or more variables (Ferguson, in press; Snyder & Lawson, 1993). As with all statistical tools, effect size estimates are just that, estimates. Mostly, effect sizes are resistant to sample size influence, and thus provide a truer measure of the magnitude of effect between variables.

Effect sizes seen in the social sciences are oftentimes very small (Rosnow & Rosenthal, 2003). This has led to difficulties in their interpretation. There is no agreement on what magnitude of effect is necessary to establish practical significance. Cohen (1992) of-
fers the value of $r = .1$, as a cut-off for “small” effects (which would indicate only a 1% overlap in variance between two variables). However, Cohen did not anchor his recommendations across effect sizes; as such, his recommendations for $r$ and $d$ ultimately differ in magnitude when translated from one to another. For instance, Cohen suggests that $r = .3$ and $d = .5$ each indicate a cut-off for moderate effects, yet $r = .3$ is not the equivalent of $d = .5$. Other scholars suggest a minimum of $r = .2$ (Franzblau, 1958; Lipsey, 1998) or $.3$ (Hinkle, Weirsmar, & Jurs, 1988). In the current article, all effect size recommendations, where possible, are anchored to a minimum of $r = .2$, for practical significance (Franzblau, 1958; Lipsey, 1998). These readily convert from $r$ to $d$ for instance, without altering the interpretation. Note that this is a suggested minimum not a guarantee that observed effect sizes larger than $r = .2$ are practically significant. Such cut-offs are merely guidelines, and should not be applied rigidly (Cohen, 1992; Snyder & Lawson, 1993; Thompson, 2002).

Table 1 presents suggestions for effect size interpretation based on several previous reviews (Franzblau, 1958; Lipsey, 1998), although scholars are cautioned that effect size interpretation should be context specific, weighing the merits and potential unreliability of the study methodology against potential real-world impact of small or large effects.

Effect sizes can be thought of as falling into four general categories (Kline, 2004; Vacha-Haase & Thompson, 2004):

1. Group difference indices. As the name implies, these estimates usually note the magnitude of difference between two or more groups. Cohen’s $d$ is an example here.

2. Strength of association indices. These estimates usually examine the magnitude of shared variance between two or more variables. Pearson $r$ is an example.

3. Corrected estimates. These measures, such as the adjusted $R^2$ correct for sampling error because of smaller sample sizes.

4. Risk estimates. These measures compare relative risk for a particular outcome between two or more groups. More commonly used in medical outcome research, these include relative risk (RR) and odds ratio (OR).

**Group Difference Indices**

Group difference indices lend themselves nicely to categorical or experimental outcomes rather than continuous or correlational data. The most commonly used such measure is Cohen’s $d$ (Cohen, 1969). Cohen’s $d$ is a rather simple statistical expression, namely the difference between two group outcomes divided by the population standard deviation. This is represented in the following formula: $d = (\mu_1 - \mu_2)/\sigma$.

The population standard deviation is an unknown, which leads to concerns how it should be represented. Often the treatment and control group standard deviations are pooled, although this results in problems in the event of multiple comparisons, such as in ANOVA designs. The population standard deviation estimate may vary from one contrast to another in such designs.

Glass proposed an alternate called delta ($\Delta$), which substitutes the control group’s standard deviation for the population standard deviation, thus standardizing the denominator variable across experimental contrasts: $\Delta = (\mu_1 - \mu_2)/SD_{Control}$.

Delta assumes an experimental design with a default control group that is representative of the population from which the samples are drawn. Delta would be less applicable for contrasts in which no clear control group exists (e.g., comparing males vs. females).

Hedges (1981) proposed a slightly different fix, in his statistic $g$, by pooling the standard deviations of all experimental groups and the control group resulting in a single standard deviation estimate. Although the resultant estimate is not really a great estimate of $\sigma$, it is more standardized than either $d$ or $\Delta$ and as such may represent the best option for ANOVA designs.

Sapp, Obiakor, Gregas, and Scholze (2007) discuss a multivariate alternative for $d$ with use with multiple dependent variables. This is represented by the formula $D^2 = (y_1 - y_2)S^{-1}(y_1 - y_2)$, where $(y_1, y_2)$ is a vector of means and $S^{-1}$ is the inverse of the sample covariance matrix. It is recommended that individuals interested in using $D^2$ consult Sapp, Obiakor, Gregas, and Scholze (2007) for a detailed discussion.

**Strength of Association Indices**

Strength of association indices estimate the shared variance between two or more variables. Arguably, they are more accurate for continuous data than are indices such as $d$, while maintaining usefulness is representing the effect size for categorical and experimental data. Most experimental outcomes using $r$ or $F$ statistics can be readily converted to the Pearson $r$ (see Rosenthal & DiMatteo [2001] and Rosnow & Rosenthal [2003] for relevant formulas).

The most commonly used strength of association measure is Pearson’s $r$ that indicates the degree of shared variance between

<table>
<thead>
<tr>
<th>Type of effect size estimate</th>
<th>Included indices</th>
<th>RMPE</th>
<th>Moderate effect</th>
<th>Strong effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group difference</td>
<td>$d$, $\Delta$, $g$</td>
<td>.41</td>
<td>1.15</td>
<td>2.70</td>
</tr>
<tr>
<td>Strength of association</td>
<td>$r$, $R$, $\varphi$, $p$, partial $r$, $\beta$, $\eta$, $\rho_A$</td>
<td>.2</td>
<td>.5</td>
<td>.8</td>
</tr>
<tr>
<td>Squared association indices</td>
<td>$r^2$, $R^2$, $\eta^2$, adjusted $R^2$, $w^2$, $e^2$</td>
<td>.04</td>
<td>.25</td>
<td>.64</td>
</tr>
<tr>
<td>Risk estimates</td>
<td>RR, OR</td>
<td>2.0*</td>
<td>3.0</td>
<td>4.0</td>
</tr>
</tbody>
</table>

Note. RMPE = recommended minimum effect size representing a “practically” significant effect for social science data. For effects with highly valid dependent measures (e.g., death) and using rigorous controlled outcome trials, lower values may have practical value. RR = relative risk; OR = odds ratio.

* These are not anchored to $r$ and should be interpreted with caution.
two variables. \(R, R^2, \eta^2, \varphi, \) and Cramer’s \(V\) are all related indices. \(R\) and \(R^2\) in their unadjusted form are largely multiple regression equivalents of \(r\) and \(r^2\) and generally indicate the strength of association between one dependent variable and multiple predictors. Cramer’s \(V\) is typically used to represent the strength of association from chi-squared analyses as represented by the following formula: \(V = \frac{\chi^2/N \times (k - 1)}{1/2}.\) In the event of a \(2 \times 2\) table, the similar \(\varphi\) statistic is used: \(\varphi = \left[\frac{\chi^2}{N}\right]^{1/2}.

In this formula, \(k\) represents the minimal number of either rows or columns in the chi-squared display. One cautionary note about \(\varphi\) is in order. Some scholars have attempted to use \(\varphi\) to calculate effect size estimates from binomial medical epidemiology research (Rosnow & Rosenthal, 2003). This is a flawed approach as it corrupts the treatment effect size with that of the disease’s own effect, producing a largely irrelevant interaction term effect size, not the effect size for treatment itself (Crow, 1991; Ferguson, in press; Hsu, 2004; Kraemer, 2005). Attempting to compute \(\varphi\) from such data results in a severely attenuated effect size estimate. This approach has been long recognized as flawed (Crow, 1991; Hsu, 2004; Kraemer, 2005), yet continues to be used.

As an example, Rosnow and Rosenthal (2003) discuss the effectiveness of the Salk vaccine on polio. From a treatment group \((n = 200,745)\) receiving the Salk vaccine, 33 later had polio develop. From a control group \((n = 201,229)\), polio developed in 115. Although the relative risk of not receiving the Salk vaccine is a moderate 3.48, the authors calculate \(\varphi = .011\) (square root of \(\varphi^2 = 45.52 \div n = 401,975\)), barely different from no effect at all. What if Salk was 100% effective in preventing polio (which should conceptually correspond to \(r = 1.00\))? Observing the maximum \(\varphi\), we observe that this barely changes with \(\varphi_{\max} = .017\) (\(\chi^2 = 114.74, n = 401,975\)). In other words, the range of possible values for \(\varphi\) in the Salk vaccine trial instead of ranging from 0 to 1.00 as they should, ranges only from 0 to .017. This is clearly problematic. The problem is that the formula uses sample size. Dividing any value of \(\chi^2\) by \(n = 401,975\) will result in artificially low scores. Because the epidemiologists who studied the Salk vaccine have no way of knowing who might be exposed to polio in advance, they used a wide “net” sampling approach. Most of the resultant sample were never exposed to polio, and thus are irrelevant to the hypothesis “How effective is the Salk vaccine in preventing polio in individuals exposed to polio?” The \(\chi^2\) method (Ferguson, in press) accounts for this sampling problem by comparing only those individuals likely to have been exposed to polio. From the control group, we know that approximately 115 individuals can be expected to have polio develop. If Salk is completely ineffective, we would expect approximately 115 to have polio develop in the treatment groups as well (adjusting for any differences in sample size). However, only 33 have polio develop and 82 do not. Developing a binomial effect size display from these data, we find that for individuals actually likely to have been exposed to polio, \(r = .744 (\chi^2 = 127.43, n = 230), \) not .011. This effect size is likely a better index of the actual effectiveness of the Salk vaccine and makes more sense given an \(R^2\) of 3.48.

One further note about \(r\) is that the Pearson \(r\) works best with continuous and normally distributed data. It is important that the proper correlational method is used, otherwise resultant effect sizes will likely be truncated. For instance, ordinal data, or data that is nonnormally distributed, may be better handled by the Spearman rho \((\rho)\) than Pearson \(r\). Overall, it is argued here that \(r\) is a better effect size indicator for most psychological data than is \(d\), as it provides the most accurate representation of continuous as well as categorical data, is well known and easy to interpret. As a cautionary note Wang and Thompson (2006) have indicated that \(r\) can be positively biased, particularly with small samples. They suggest using either the Ezekiel formula \(1 - [(n - 1)/(n - p - 1)][1 - R^2]\) or Smith formula \(1 - \frac{n}{(n - p)}(1 - R^2)\) as corrections. The Wherry \(1 - [(n - 1)/(n - k - 1)] + (1 - R^2)\) and Lord formulas \(1 - (1 - R^2) \times [(n + k + 1)/(n - k - 1)]\) (see Snyder & Lawson, 1993) can also be used to replace \(R^2\) (in both formulas \(k\) represents the number of predictor variables.) The Lord formula is the more conservative of the two, and some scholars have cautioned against use of Wherry (Sapp, 2006). In place of Wherry, the Herzberg formula \(1 - [(n - 1)/(n - k - 1)] \times [(n + k + 1)/n](1 - R^2)\) may be supplemented (Sapp, 2006).

Pearson \(r\) and \(d\) can be readily converted from one to the other using the following formulas:

\[
\begin{align*}
  r &= \left[\frac{d^2}{(d^2 + 4)}\right]^{1/2} \\
  d &= 2r(1 - r^2)^{1/2}
\end{align*}
\]

Eta-squared \((\eta^2)\) is a commonly reported index. \(\eta^2\) is typically represented as a ratio of variance terms (Nunnally & Bernstein, 1994; Sink & Stroh, 2006):

\[
\frac{SS_{between}/SS_{total}}{\sigma_{total}^2/\sigma_{total}^2}
\]

\(\eta^2\) (or partial \(\eta^2\)) is most commonly used for factorial ANOVA designs, owing to its standardized availability through SPSS. \(\eta^2\) is generally a better index of curvilinear relationships than is \(r\), with the result that \(\eta^2\) estimates tend to be slightly higher in magnitude than \(r^2\) estimates. \(\eta^2\) estimates are interpreted more or less similarly to \(r^2\) estimates with the size of the relationship indicating shared variance between two variables, or explained by an interaction term. Levine and Hullett (2002) caution that \(\eta^2\) estimates may be inflated and should not be taken as equivalent to \(r^2\). Researchers are cautioned to note as well that SPSS printouts may misreport partial \(\eta^2\) estimates as \(\eta^2\) (Levine & Hullett, 2002). Partial \(\eta^2\) estimates are nonadditive (meaning they can potentially sum to greater than 100% of total variance explained). Sapp (2006) indicates that \(\eta^2\) involves division by total sample size. Partial \(\eta^2\) involves division by sample size minus number of groups. As such with large samples, the distinction between \(\eta^2\) and partial \(\eta^2\) will tend to be small.

Corrected estimates include effect size estimates that attempt to correct either for error, or shared variance because of other predictors. The former group includes adjusted \(R^2\), Hays’ \(\omega^2\), and \(\varepsilon^2\), although many of these effect size estimates see only seldom use (Kirk, 2006). The latter category includes partial \(r\), and standardized regression coefficients (\(\beta\)), which estimate the shared variance between two variables once variance attributable to other variables is controlled. Levine, Weber, Park, and Hullett (2008) express wariness about using \(\beta\) as the effect sizes seen tend to be lower than \(r\). Similarly, partial \(r\) presents the strength of association once variance attributable to a third variable has been removed. For instance if one wishes to study the relationship between video game playing and aggression, it may be necessary to remove variance because of sex, as males both play more video games and are more aggressive (Ferguson, 2007). The resultant
partial $r$ provides a better index of the unique variance shared by video games and aggression, once male sex is removed from the equations. In that sense, $\beta$ and partial $r$ may be more accurate than bivariate $r$ as an effect size estimate by eliminating extraneous variance from a relationship that may artificially inflate nonadditive effect size estimates.

$\omega^2$, and $\epsilon^2$ are most commonly used for ANOVA designs, and thus can replace $d$ or $\eta^2$. Indeed, they are recommended as a replacement for $\eta^2$ in particular (Levine & Hullett, 2002).

$$\omega^2 = \frac{SS_{\text{effect}} - df_{\text{effect}} \times MSE}{SS_{\text{total}} + MSE}$$

$$\epsilon^2 = \frac{SS_{\text{effect}} - (df_{\text{effect}} - 1) \times MSE}{SS_{\text{total}}}$$

$\epsilon^2$ tends to be larger than $\omega^2$. Both are smaller in magnitude than $r^2$ or $\eta^2$. They are, mostly, more conservative estimates of effect size and, as such, highly recommended as replacements, particularly for $\eta^2$. Note that the $\omega^2$ formula for random effects models is different from the fixed effects model presented here and can be found on page 340 of Snyder and Lawson (1993).

Several indices of effect size can be used with rank-order data. The Spearman rho ($\rho$) mentioned earlier is one of these. Kendall’s $\tau$ provides an effect size estimate based on the number of concordant pairs in two rank orders (Kendall, 1938). Gamma is a somewhat similar measure, measuring the strength of association between concordant rank ordered pairs (Sapp, 2006). Somer’s $d$ is similar to Gamma, although asymmetrical in nature with presumed cause and effect variables. All four measures have value ranges identical to $r$ although they are superior for rank-order data.

### Risk Estimates

Risk estimate measures are more commonly used in medical research. They estimate the difference in risk for a particular outcome between two or more groups of individuals. Three main risk estimates in use include RR, OR, and risk difference (RD). Table 2 refers to the binomial display used in biomedical treatment outcome research.

All risk estimates are formed from ratios of individuals in each of the cells presented in Table 2. RR is a ratio of patients in a control group who contract an illness or condition to those in the treatment group who contract the same condition and is represented as (Bewick, Cheek, & Ball, 2004; Rosnow & Rosenthal, 2003):

$$\text{RR} = \frac{A}{(A + B)} \times \frac{C}{(C + D)}$$

An RR of 1.0 indicates no difference in risk between the two groups. Below 1.0 indicates less risk for the control group than treatment group (“control” group is used broadly, indicating any risk assumed in the hypothesis to have the greater risk and should not be taken to restrict RR to experimental designs only). An RR of 2.0 would indicate that the “control” group is twice as likely to demonstrate a given condition than the “treatment” group (thus, they have 100% greater risk). As an example, the American Cancer Society (2008) estimates the RR for smoking and lung cancer to be approximately 23 for male smokers. This means that male smokers are 23 times more likely to have lung cancer develop than male nonsmokers.

Just as with effect sizes seen more commonly in the social sciences, interpretation of RR can be context specific, depending upon the initial base risk of the disease. However, RR values between 1.0 and 2.0 are unlikely to have much practical value, and these small effects are likely to be highly unreliable and contradictory across studies. Indeed a plethora of observational studies with small RR effects have linked a little of this with a little of that in terms of purported harmful (or beneficial) factors on health that ultimately were found to be of little value (Smith & Ebrahim, 2001). However, researchers are reminded that RR must be interpreted by examining the actual base risk of the treatment group (i.e., lower risk group). An RR of 2.0 might not be terribly meaningful if the base risk is 1% but may be more meaningful if the base risk is 10%.

RR is likely a better estimate of effects for binomial data than efforts to translate the same data into $r$. As such, it is recommended that psychological researchers become more familiar and comfortable with the use of RR as it may be superior to $r$ for certain kinds of data, particularly binomial data.

The OR is a similar effect index using the following formula (Bewick, Cheek, & Ball, 2004; Rosnow & Rosenthal, 2003):

$$\text{OR} = \frac{(A/B)}{(C/D)}$$

OR represents the odds of control patients contracting a condition in proportion with treatment patients contracting a condition. So long as the risks of the disease are low, OR will approximate RR (Bewick, Cheek, & Ball, 2004). Davies, Crombie, and Tavakoli (1999) note that this approximate relationship breaks down when the risk in either group rises above 20%, with OR and RR becoming increasingly disparate. The problem with the OR as indicated by Rosnow and Rosenthal (2003) is that when the denominator terms become very small (i.e., few people survive or are unaffected), the OR can potentially accelerate to infinity. ORs greater than 3.0 (or less than 0.33 when the control group is less affected) are considered to be moderately strong (Haddock, Rindskopf, & Shadish, 1998). As with RR, the base risk must be considered with interpreting OR.

RD represents the difference between the proportion of control patients who contract a condition and the proportion of treatment patients who contract a condition. It is represented by the following formula (Bewick, Cheek, & Ball, 2004; Rosnow & Rosenthal, 2003):

$$\text{RD} = \frac{A}{(A + B)} - \frac{C}{(C + D)}$$

RD is fairly easy to interpret, representing the actual difference in risks between two groups. For instance RD = .04 represents a 4% risk difference between the control and treatment groups. Evaluating the clinical or practical significance of RD is trickier than with other measures. For instance, RD = .04 may be clini-
cally insignificant if the compared risks are 76% and 80%, but very significant if the compared risks are 1% and 5%.

Other Indices

Counternull

The counternull value of the effect size is the nonnull magnitude of effect that is equally supported by the data as a null effect itself (Rosenthal & Rubin, 1994). For most group difference effect sizes, this value is simply twice the observed effect size. So, for \( d = .2 \) with a nonsignificant result, the actual effect in the population is as equally likely to be \( d = .4 \) as it is \( d = .0 \). The counternull is intended to remind researchers that a nonsignificant result does not mean zero effect size, and that significant results do not necessarily mean practical importance.

Number Needed To Treat

The number needed to treat (NNT; Pinson & Gray, 2003) refers to the number of individuals who would need to receive treatment to produce one more positive response. For instance, a NNT of three would indicate that three patients would need to receive treatment for one more patient to show improvement than would have under no treatment. NNT works best with dichotomous outcomes (i.e., success/failure). NNT is influenced by the baseline rate of the disease in the population of interest (Pinson & Gray, 2003). NNT, as such provides a reasonably intuitive indices for evaluating the outcome of clinical trials. For example, if 70% of patients did not respond to a placebo treatment and 20% did not respond to an experimental treatment, this difference would be 50% or .5. NNT is the inverse of this \( 1/5 = 2 \), meaning that two patients would need to receive treatment for one more positive response than under placebo.

A Note on Practical Significance

In many respects, effect size estimates provide greater information for judgments about practical significance than does NHST. Yet, judgments about practical significance need to consider several issues. The quality of measurement and sampling strategies both have the potential to inflate or attenuate effect size estimates. For instance, an \( r^2 \) of .01 is likely to have much greater practical impact when the outcome is death or serious morbidity. The same effect size for a weakly validated interval/ratio-scale measure of behavior within individuals may be essentially nonnoticeable in the “real world.” In addition, researchers may need to consider the risks and benefits of a particular intervention. An intervention with a weak effect size but no risks may be valuable. That same intervention may be less desirable if the risks are considerable. An intervention that causes a 1% decline in the rate of death for a particular disease may be valuable no matter what the risks (because no one can be deader than dead). By contrast, a depression treatment that reduces depressed mood only 1% may not be worth the financial costs accrued to patients.

A recent clinical trial of circumcision used to prevent HIV among Kenyan men found that of 1,391 men randomized to circumcision, 22 later had HIV, whereas 47 in the control uncircumcised group of 1,393 became HIV positive (Bailey et al., 2007). This is approximately a 53% reduction in risk, corresponding to an RR for uncircumcised males of 2.13 (95% CI 1.30-3.53). Although the effect size is small, the authors considered these results significant enough to stop the trial and offer circumcision to men in the control group. As such, it is important to use some critical thinking and perspective when evaluating practical significance. Bailey et al. (2007) represents a well-run randomized clinical outcome trial with a highly valid dependent variable (HIV-positive serum test). The interpretation applied to Bailey et al. should not be assumed to apply to all psychological studies, particularly with measures for which validity is weak or not known, or clinical cut-offs with established sensitivity and specificity are absent.

Some General Recommendations

The following guidelines are offered to assist in the choice of effect size measures and their interpretation.

1. Guidelines for the interpretation of many effect sizes are offered as part of this article. As noted by numerous scholars (e.g., Cohen, 1992; Snyder & Lawson, 1993; Thompson, 2002), rigid adherence to arbitrary guidelines is not recommended. However, this admonition should not be taken as license for the overinterpretation of weak effect sizes. Guidelines are suggested as minimum cut-offs, not guarantees that effect sizes exceeding those cut-offs are meaningful. Study limitations, failure to control for other relevant predictors or threats to internal validity, the reliability and validity of responses to the measures used, etc., should be considered when interpreting effect size.

2. Corrected effect sizes are preferable to uncorrected effect sizes. With the exception of adjusted \( R^2 \) these unfortunately require more by-hand calculation on the part of experimenters. Nonetheless, the corrected effect size estimates presented are likely to be more accurate estimates of the effect size in the population of interest.

3. For correlational designs, partial \( r \) and standardized regression coefficients are superior to bivariate \( r \) as they estimate the unique variance attributable to a predictor controlling for other variables. These estimates help to reduce nonadditive illusory correlations (that can sum to greater than 100% of explained variance) that overestimate the unique predictive value of variables.

4. Efforts to translate RR or OR into \( r \) or \( d \) should be discontinued. If such translations absolutely must be done, only \( r_s \) should be used as an effect size estimate when the data are binomial.

5. Somer’s \( d \) or Kendall’s \( \tau \) should be used instead of \( r \) or \( d \) for ordinal data.

6. It is recommended that effect size CIs be reported along with effect size estimates (Sapp, 2004; Wilkinson et al., 1999). Effect size CIs that cross zero suggest that the null hypothesis should not be rejected (Sapp, 2004). Thus, the use of CIs provides more information than point estimates alone, and interpretations of effect size estimates should include analysis of their CI.
7. Although effect size is meant to represent a “true” effect in the population, it is important to understand that effect size estimates can be influenced by sampling and measurement. Samples that are too small, or that are non-random may produce biased effect size estimates that should be interpreted with caution. Various methodological issues can also influence effect size. Sample responses that demonstrate poor reliability on a measure may lower effect size estimates. By contrast, poorly standardized measures may inadvertently result in inflated effect size estimates if they allow researchers to select from multiple potential outcomes (Ferguson, 2007). Effect sizes also can vary depending upon the statistical methods used. Statistical methods that reduce variance, such as using false dichotomies, may truncate effect size estimates. Research designs that fail to control for extraneous variables will tend to produce higher effect sizes than those that adequately control extraneous variables if those variables are highly correlated with the independent and dependent measures (Olejnic & Algina, 2003). The use of parametric statistics when the assumptions of such tests have been violated may also produce biased effect size estimates. For instance, even with medical epidemiological studies, it has been observed that correlation outcomes, particularly those with weak effect sizes, often prove unreliable under scrutiny (Smith & Ebrahimi, 2001).

Conclusion

This article presents a number of commonly used and important effect size measures. It is worth noting that it is not possible to describe all effect size measures available as they are quite numerous. There are several resources to which the reader is referred for further discussion (e.g., Cohen 1992; Sapp, 2006).

The current article is intended as an introductory primer for researchers who may not be familiar with the range of effect size estimates available to them, and when they should be used. No effect size measure is perfect for all situations, and some disagreement persists over the advantages of some over others. This article is intended as a general guideline. Ultimately, researchers are encouraged to select wisely (and conservatively) from among the options presented. Interpretation of effect sizes will always remain context specific. Accepting effect sizes of any magnitude as clinically or practically significant renders their usefulness as moot. Psychologists must be willing to objectively identify minute effects and interpret them as such. Only by being realistic will we know when we are actually on to something.

References


Ferguson, C. J. (in press). Is psychological research really as good as medical research? Effect size comparisons between psychology and medicine. Review of General Psychology.


Loftus, G. (1996). Psychology will be a much better science when we change the way we analyze data. Current Directions in Psychological Science, 5, 161–171.


Olejnic, S., & Algina, J. (2003). Generalized eta and omega squared...
statistics: Measures of effect size for some common research designs. *Psychological Methods, 8,* 434–447.

Received January 5, 2009
Revision received February 24, 2009
Accepted March 2, 2009